Tag: investors

TORONTO, June 10, 2025 (GLOBE NEWSWIRE) -- Timbercreek Financial Corp. (TSX: TF) (the "Company") announced today that it has obtained the approval of the Toronto Stock Exchange (the "TSX") to commence a normal course issuer bid (the “NCIB”) with respect to its common shares (the “Shares”). The NCIB will commence on June 12, 2025 and will terminate on the earlier of June 11, 2026 or the date on which the Company has purchased the maximum number of Shares permitted under the NCIB.

HOUSTON, June 10, 2025 (GLOBE NEWSWIRE) -- Whitestone REIT (NYSE: WSR) (“Whitestone” or the “Company”) today announced that its Board of Trustees has declared a monthly cash dividend of $0.045 per share on the Company's common shares and operating partnership units for the third quarter of 2025.   The dividend represents a quarterly amount of $0.135 per share, and an annualized amount of $0.54 per share.

Declares Quarterly Cash Dividend Of $0.50 Per Share

Heineken Holding N.V. reports transactions under its current share buyback programme

Ingelheim, Germany, and San Francisco, Calif., June 10, 2025 | Boehringer Ingelheim, a global leader in animal health, and Eko Health, a pioneer in applying artificial intelligence (AI) for early detection of heart and lung diseases, have entered a strategic collaboration agreement. This collaboration brings together Boehringer’s depth in canine cardiology with Eko Health’s powerful AI algorithms and digital stethoscopes – already trusted by healthcare professionals worldwide, with over 650,000 devices sold for use in human medicine. Leveraging their combined expertise, along with Boehringer’s proprietary algorithm developed with support from leading veterinary cardiologists worldwide, the partnership aims to enhance the early detection and diagnosis of heart disease in dogs. A canine-specific detection algorithm will be made available to veterinarians through a purpose-built Eko mobile app launching in 2026.

Tuebingen, Germany, June 10, 2025 – HepaRegeniX GmbH (“HepaRegeniX”), a clinical-stage company advancing novel therapies to treat acute and chronic liver disease, today announced that the first patient has been dosed in their Phase Ib clinical trial of its lead candidate HRX-215. The trial is evaluating the safety and efficacy of HRX-215, an orally available small-molecule inhibitor of MKK4, in patients undergoing partial liver resection due to liver metastases deriving from colorectal cancer. HXR-215 is designed to treat advanced-stage liver disease by increasing the regenerative capacity of hepatocytes. An initial data readout is planned for the second half of 2025.

Alm. Brand A/S share buy-back program

Press Release